Prognostic value of TyG index for in-hospital adverse cardiovascular events in patients with acute myocardial infarction
ZHOU Xiang, LIU Ruihan, LIU Yutong, TIAN Fan, ZHANG Jie, WANG Xiaomao, CAO Jian
the 4th Healthcare Department of the Second Medical Center of PLA General Hospital/National Clinical Research Center for Geriatric diseases, Beijing 100853, China
Abstract：Objective To investigate the association between the triglyceride-glucose(TyG) index and in-hospital major adverse cardiovascular events(MACE) in patients with acute myocardial infarction(AMI) based on propensity score matching (PSM) method. Methods A retrospective analysis was conducted on 769 AMI patients admitted to the First Medical Center of PLA General Hospital from January 2022 to May 2024. The patients were divided into non-MACE and MACE groups based on the occurrence of MACE. PSM was used for 1:1 matching to balance the baseline data between the two groups. Clinical data after matching were compared, and the relationship between the TyG index and in-hospital MACE in AMI patients was analyzed using multivariable logistic regression. Results A total of 132 patients experienced in-hospital MACE. Before PSM, there were significant differences in age, smoking history, drinking history, diabetes history, and stroke history between the two groups (P<0.05). After PSM, 258 cases were obtained, and the comparison between the groups was balanced. After PSM, the MACE group had higher levels of heart rate, C-reactive protein (CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), TyG index, and higher proportions of renal dysfunction, liver dysfunction, intra-aortic balloon pumping(IABP), and extracorporeal membrane oxygenation (ECMO), while the systolic blood pressure(SBP), hemoglobin(Hb), albumin levels, and the proportion of temporary pacemaker use were lower (P<0.05). Multivariable logistic regression analysis showed that after adjusting for confounding factors, TyG index [OR and 95% CI: 1.96(1.23-3.13)] was still the influential factor for MACE in hospital (P<0.05). Conclusions The incidence of in-hospital MACE of AMI patients increases with the elevation of the TyG index, and the TyG index is an independent influencing factor of the former.
周翔, 刘睿涵, 刘昱彤, 田璠, 张杰, 王小毛, 曹剑. TyG指数对急性心肌梗死患者院内不良心血管事件的预测价值[J]. 武警医学, 2025, 36(1): 25-29.
ZHOU Xiang, LIU Ruihan, LIU Yutong, TIAN Fan, ZHANG Jie, WANG Xiaomao, CAO Jian. Prognostic value of TyG index for in-hospital adverse cardiovascular events in patients with acute myocardial infarction. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(1): 25-29.
Bergmark B A, Mathenge N, Merlini P A, et al. Acute coronary syndromes [J]. Lancet(London, England), 2022, 399(10332): 1347-1358.
[2]
Barrère L S, Vincent A, Jorgensen C, et al. Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing [J]. Physiol Rev, 2024, 104(2): 659-725.
[3]
Mao Q, Zhou D, Li Y, et al. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST-segment elevation acute coronary syndrome [J]. Dis Markers, 2019, 2019: 6891537.
[4]
Wu Z, Liu L, Wang W, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study [J]. Cardiovasc Diabetol, 2022, 21(1): 142.
[5]
Zhang X, Du Y, Zhang T, et al. Prognostic significance of triglyceride-glucose index in acute coronary syndrome patients without standard modifiable cardiovascular risk factors [J]. Cardiovasc Diabetol, 2024, 23(1): 270.
[6]
Wang L, Cong H L, Zhang J X, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome [J]. Cardiovasc Diabetol, 2020, 19(1): 80.
Rosenblit P D. Extreme atherosclerotic cardiovascular disease(ASCVD) risk recognition [J]. Curr Diab Rep, 2019, 19(8): 61.
[9]
Mancusi C, De Simone G, Best L G, et al. Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the strong heart study cohort [J]. Cardiovasc Diabetol, 2019, 18(1): 56.
[10]
Tao L C, Xu J N, Wang T T, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations [J]. Cardiovasc Diabetol, 2022, 21(1): 68.
[11]
Hill M A, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease [J]. Metabolism, 2021, 119: 154766.
[12]
Simental-Mendía L E, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects [J]. Metab Syndr Relat Disord, 2008, 6(4): 299-304.
[13]
Thai P V, Tien H A, Van Minh H, et al. Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes [J]. Cardiovasc Diabetol, 2020, 19(1): 137.
[14]
Pan W, Ren Y, Yang F, et al. Triglyceride glucose index is associated with obstructive coronary artery disease in hypertensive patients [J]. Cardiovasc Diabetol, 2023, 22(1): 9.
[15]
Park G M, Cho Y R, Won K B, et al. Triglyceride glucose index is a useful marker for predicting subclinical coronary artery disease in the absence of traditional risk factors [J]. Lipids Health Dis, 2020, 19(1): 7.
[16]
Jin J L, Sun D, Cao Y X, et al. Triglyceride glucose and haemoglobin glycation index for predicting outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study [J]. Ann Med, 2018, 50(7): 576-586.
[17]
Shi Y, Duan H, Liu J, et al. Association of triglyceride glucose index with the risk of acute kidney injury in patients with coronary revascularization: a cohort study [J]. Diabetol Metab Syndr, 2024, 16(1): 117.
2025, Vol. 36 
